Sugi Predict

Sugi Predict / Compounds / SCHEMBL7706970

SCHEMBL7706970

SCHEMBL7706970

NCCCCC[C@@H]1CCSS1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.59
▸ TARDBP Q13148 2/20 0.59
▸ HSD17B10 Q99714 2/20 0.55
▸ CYP2C9 P11712 1/20 0.55
▸ MEN1 O00255 1/20 0.55
▸ NR1I2 O75469 1/20 0.55
▸ ALDH1A1 P00352 1/20 0.55
▸ LMNA P02545 1/20 0.55
▸ POLB P06746 1/20 0.55
▸ THRB P10828 1/20 0.55
▸ TSHR P16473 1/20 0.55
▸ ACHE P22303 1/20 0.55
▸ APEX1 P27695 1/20 0.55
▸ RECQL P46063 1/20 0.55
▸ BLM P54132 1/20 0.55
▸ PMP22 Q01453 1/20 0.55
▸ TDP1 Q9NUW8 1/20 0.55
▸ SAE1 Q9UBE0 1/20 0.55
▸ UBA2 Q9UBT2 1/20 0.55
▸ L3MBTL1 Q9Y468 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10424416 1.00 KMT2A (0.59) KMT2ATARDBPHSD17B10CYP2C9MEN1
SCHEMBL29249679 1.00 KMT2A (0.59) KMT2ATARDBPHSD17B10CYP2C9MEN1
SCHEMBL7841853 0.98 KMT2A (0.61) KMT2ATARDBPHSD17B10CYP2C9MEN1
SCHEMBL22140625 0.88 KMT2A (0.47) KMT2ATARDBPHSD17B10CYP2C9MEN1
SCHEMBL29263924 0.87 HSD17B10 (0.67) KMT2ATARDBPHSD17B10CYP2C9MEN1
SCHEMBL1252607 0.80 CA12 (0.65) KMT2ATARDBPHSD17B10CYP2C9MEN1
SCHEMBL16273222 0.80 CA12 (0.65) KMT2ATARDBPHSD17B10CYP2C9MEN1
SCHEMBL27519130 0.79 KMT2A (0.46) KMT2ATARDBPHSD17B10CYP2C9MEN1
SCHEMBL24071234 0.79 HSD17B10 (0.59) KMT2ATARDBPHSD17B10CYP2C9MEN1
SCHEMBL4475724 0.79 HSD17B10 (0.59) KMT2ATARDBPHSD17B10CYP2C9MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230173093-A1 CHARGE VARIANT LINKERS SEAGEN INC (US) 2023-06-08 — — US disclosed
US-20230173093-A1 CHARGE VARIANT LINKERS SEAGEN INC (US) 2023-06-08 — — US disclosed
WO-2023058673-A1 SULFUR-CONTAINING COMPOUND USEFUL FOR TREATING OR PREVENTING PRESBYOPIA OR LIKE 参天製薬株式会社 2023-04-13 — — WO disclosed
WO-2020132655-A1 ADCS WITH THIOL MULTIPLEX LINKERS SEATTLE GENETICS, INC. (US) 2020-06-25 — — WO disclosed
US-20130116284-A1 LIPOIC ACID AND NITROXIDE DERIVATIVES AND USES THEREOF RADIKAL THERAPEUTICS INC. (US) 2013-05-09 — — US disclosed
US-20130116284-A1 LIPOIC ACID AND NITROXIDE DERIVATIVES AND USES THEREOF RADIKAL THERAPEUTICS INC. (US) 2013-05-09 — — US disclosed
WO-2011141909-A2 LIPOIC ACID AND NITROXIDE DERIVATIVES AND USES THEREOF RADIKAL THERAPEUTICS INC. (US) 2011-11-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230173093-A1 CHARGE VARIANT LINKERS SSB, UACA, CDA KMT2A 199/4885TARDBP 882/4885HSD17B10 2163/4885
US-20130116284-A1 LIPOIC ACID AND NITROXIDE DERIVATIVES AND USES THEREOF PARP1, PARP2, PARP6 KMT2A 1777/4885TARDBP 875/4885HSD17B10 592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.